montgomery women's medical center pc – FDA Warning Letter, Jan 21, 2020
On May 14, 2020, the FDA issued a Warning Letter to Montgomery Fertility Center following an inspection from January 8-21, 2020. The inspection revealed significant deviations from 21 CFR Part 1271 regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps).
Key violations include: 1. **Failure to test for communicable disease agents (21 CFR 1271.55(a))**: Anonymous oocyte donors were not tested for HIV-1, HCV, and HBV by NAT, nor for West Nile Virus (WNV) during the specified period (June 1st - October 31st). 2. **Failure to screen donors for risk factors (21 CFR 1271.75(a)(1))**: The donor medical history questionnaire lacked screening for all relevant communicable disease risks, specifically Zika Virus (ZIKV) exposure within the past 6 months (only asked for 120 days) and did not include all CDC-identified ZIKV risk areas. Some donor questionnaires also had missing answers for ZIKV risk screening.
The FDA acknowledged the firm's January 27, 2020, response to the FDA-483. While procedures were updated for HIV-1/HCV/HBV NAT and WNV testing, donor eligibility determinations for
ID · f9c2b6b2-542d-4768-b7ac-82570a80722c
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.